In the claims

18. (currently amended): ~~A composition comprising a~~ An antibody which specifically reacts with a ~~human IL-11R~~ protein comprising an amino acid sequence from SEQ ID NO:2 selected from the group consisting of amino acids 26 to 111, amino acids 112 to 365, amino acids 366 to 390, and amino acids 391 to 422.

39. (currently amended): The ~~composition~~ antibody of claim 18, wherein said antibody is a neutralizing antibody.

40. (currently amended): The ~~composition~~ antibody of claim 18, wherein said antibody blocks binding of IL-11 to a human IL-11 receptor.

41. (currently amended): The ~~composition~~ antibody of claim 18, wherein said antibody is a polyclonal antibody.

42. (currently amended): The ~~composition~~ antibody of claim 18, wherein said antibody is a monoclonal antibody.

43. (currently amended): The ~~composition~~ antibody of claim 18, wherein said antibody specifically reacts with a ~~human IL-11R~~ protein comprising the amino acid sequence of SEQ ID NO:2.

44. (currently amended): The ~~composition~~ antibody of claim 18, wherein said antibody specifically reacts with a ~~human IL-11R~~ protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids ~~24~~ 26 to 422.

45. (currently amended): The ~~composition~~ antibody of claim 18, wherein said antibody specifically reacts with a ~~human IL-11R~~ protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids ~~24~~ 26 to 365.

46. (currently amended): The ~~composition~~ antibody of claim 18, wherein said antibody specifically reacts with a ~~human IL-11R~~ protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids 391 to 422.

47. (currently amended): The ~~composition~~ antibody of claim 18, wherein said antibody specifically reacts with a ~~human IL-11R~~ protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids ~~102~~ 112 to 422.

48. (currently amended): The ~~composition~~ antibody of claim 18, wherein said antibody specifically reacts with a ~~human IL-11R~~ protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids ~~102~~ 112 to 365.

49. (currently amended): The ~~composition~~ antibody of claim 18, wherein said antibody specifically reacts with a ~~human IL-11R~~ protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids ~~24~~ 26 to 359.

50. (currently amended): The ~~composition~~ antibody of claim 18, wherein said antibody specifically reacts with a ~~human IL-11R~~ protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids ~~24~~ 26 to 345.

51. (currently amended): The ~~composition~~ antibody of claim 18, wherein said antibody specifically reacts with a ~~human IL-11R~~ protein comprising the amino acid sequence of SEQ ID NO:2 from amino acids ~~24~~ 26 to 324.

52. (currently amended): The ~~composition~~ antibody of claim ~~18~~ 62, wherein said antibody is obtained using as an immunogen a ~~human IL-11R~~ protein with a cysteine residue at the carboxyl terminus, wherein said protein comprises an amino acid sequence from SEQ ID NO:2 selected from the group consisting of amino acids 26 to 111, amino acids 112 to 365, amino acids 366 to 390, and amino acids 391 to 422.

53. (currently amended): The ~~composition~~ antibody of claim ~~18~~ 62, wherein said antibody is obtained using as an immunogen a ~~human IL-11R~~ protein with tyrosine residues replaced with sulfated tyrosine residues.

54. (cancelled)

55. (currently amended): The ~~composition~~ antibody of claim ~~18~~ 62, wherein said ~~antibody obtained using as an~~ immunogen ~~a human IL-11R protein~~ is conjugated to a hapten.

56. (currently amended): The ~~composition~~ antibody of claim 55, wherein said hapten is keyhole limpet hemocyanin (KLH).

57. (currently amended): A pharmaceutical composition comprising the ~~composition~~ antibody of claim 18 and a pharmaceutically acceptable carrier.

58. (currently amended): A ~~composition comprising a~~ neutralizing ~~monoclonal~~ antibody that binds specifically to ~~an IL-11R~~ protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2 from amino acids 26 to 111, SEQ ID NO:2 from amino acids 112 to 365, SEQ ID NO:2 from 366 to 390, and SEQ ID NO:2 from 391 to 422, wherein said neutralizing antibody blocks binding of IL-11 to a human IL-11 receptor.

59. (previously added): A pharmaceutical composition comprising the composition of claim 58 and a pharmaceutically acceptable carrier.

60. (newly added): The antibody of claim 18, wherein said antibody specifically reacts with a protein comprising an amino acid sequence of SEQ ID NO:2 from 26 to 111.

61 (newly added): The antibody of claim 18, wherein said antibody specifically reacts with a protein comprising an amino acid sequence of SEQ ID NO:2 from 366 to 390.

62 (newly added): An antibody obtained using as an immunogen a protein comprising an amino acid sequence from SEQ ID NO:2 selected from the group consisting of amino acids 26 to 111, amino acids 112 to 365, amino acids 366 to 390, and amino acids 391 to 422.

63 (newly added): The antibody of claim 18, wherein said antibody is an isolated antibody.

64 (newly added): The antibody of claim 58, wherein said antibody is an isolated antibody.

65 (newly added): The antibody of claim 62, wherein said antibody is an isolated antibody.